News
The Licensing Executives Society (LES) USA-Canada annual meeting is taking place in San Diego from October 18-21, 2026. Three members of the NIH Technology Transfer Community will be speaking. NIH Office of Technology Transfer Director Tara Kirby will be speaking on the panel Evolving Best Practices
Age-related macular degeneration (AMD) affects approximately 200 million people worldwide and is the leading cause of blindness in all developed countries. Identifying eyes at high risk of progression to late-stage AMD would allow timely medical treatments, lifestyle interventions, more tailored
Ellipsoid zone (EZ) loss has been proposed as evidence of progression of several retinal degenerative diseases, including, but not limited to, retinitis pigmentosa and hydroxychloroquine (HCQ)-induced retinal toxicity. HCQ is a first-line drug used to treat autoimmune diseases such as systemic lupus
Glaucoma is one of the world’s leading causes of irreversible blindness, and currently, no therapies exist to directly protect retinal ganglion cells (RGC) from degradation and loss. NIH inventors have developed a method to treat glaucoma using exosomes derived from bone marrow-derived mesenchymal